This is consistent with our finding that low LRP2 predicts poor prognosis in the METABRIC cohort and supports that further studies should be conducted in order to evaluate LRP2 as biomarker in invasive breast carcinomas. The gene discussed is LRP2; the disease is invasive breast carcinoma.